What is the next big thing for your company's portfolio?
To help pharmaceutical companies answer this question, Kaiser Associates conducted a comprehensive analysis of nearly every pharma R&D program in the world and compiled the findings into the third annual Hot Indications List.
The 2017 edition focuses on the Therapeutic Areas and Indications with the most dynamic investment from 2015-2016.
It also includes:
- An updated Top 200 List of indications
- Insights on recent acquisitions, drug approvals, and pipeline activity
Complete the form to download your free whitepaper now!